Experience in the use of dynamic quadripolar radiofrequency exposure in the treatment of patients with urogynecological diseases

• Nina V. Zarochentseva
• Lela K. Dzhidzhikhia
• Vusala N. Nabieva

Abstract

Background. Genitourinary menopausal syndrome (GUMS) is a wide range of vaginal and urinary symptoms caused by a lack of estrogen during menopause. There are many methods of treating this pathology. It seems relevant to analyze the possibilities of all the approaches used to treat GUMS.

Аш. Evaluation of the effectiveness and safety of dynamic quadripolar radio frequency (DQRF^TM) in the treatment of women with GUMS and mild stress urinary incontinence (SUI) with concomitant dystrophic diseases of the vulva.

Material and methods. The study included 22 patients who underwent radiofrequency therapy of the genitourinary system with genitourinary menopausal syndrome in combination with dystrophic diseases of the vulva (vulvar sclerosing lichen, vulvar leukoplakia) (54.5%) and with mild stress urinary incontinence in combination with vulvar sclerosing lichen (45.5%). The treatment cycle was 3 radio wave exposures with an interval of 14 days.

The information material includes data from scientific articles available in the Pubmed database, the Eli-brary.ru Scientific Electronic Library, on this topic and published over the past years.

Results. Satisfaction with the results of treatment exceeded 75 and 65% in the two groups, respectively. The patients tolerated this manipulation well, without side effects, with a good clinical effect for 6 months. There was a decrease in the intensity of all symptoms (dryness, burning, pain in the vulva and the frequency of urination). The majority of women (60%) indicated a rapid relief of mild SUI symptoms. The positive results of treatment were maintained in the patients for 6 months. After DCR therapy, women did not notice restrictions on sexual activity and sexual discomfort.

Conclusion. DQRF^TM is a painless, safe and effective method of treating GUS, mild urinary incontinence with a predominance of a stress component, sexual dysfunction, as well as concomitant dystrophic diseases of the vulva and does not contradict the latest recommendations of professional societies on menopause.

Keywords:genitourinary syndrome, hormone therapy, estrogens, DQRF™

REFERENCES

1. Portman D.J., Gass M.L. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society. Menopause. 2014; 21 (10): 1063-8. DOI: https://doi.org/10.1097/GME.0000000000000329

2. Balan V.E., Kovaleva L.A., Tikhomirova E.V. Genitourinary or urogen-tical syndrome: possibilities of long-term therapy. Meditsinskiy sovet [Medical Advice]. 2016; (12): 98-101. DOI: https://doi.org/10.21518/2079-701X-2016-12-98-101 (in Russian)

3. Shifren J.L. Genitourinary Syndrome of Menopause. Clin Obstet Gynecol. 2018; 61 (3): 508-16. DOI: https://doi.org/10.1097/GRF.0000000000000380

4. Gandhi J., Chen A. Dagur G., Suh Y., Smith N., Cali B., Khan S.A. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016; Vol. 215 (6): 704-11. DOI: https://doi.org/10.1016/j.ajog.2016.07.045

5. Moral E., Delgado J.L., Carmona F., Caballero B., Guillan C, Gonzalez PM, et al. Genitourinary syndrome of menopause. Prevalence and quality of life in Spanish postmenopausal women. The GENISSE study. Climacteric. 2018; 21 (2): 167-73. DOI: https://doi.org/10.1080/13697137.2017.1421921

6. Monz D., Pons M., Hampel C., Hunskaer S., Quail D., Samsioe G. Sykes D., Wagg A. Papanicolaou S. Patient-repoted impact of urinary incontinence. Results from treatment seeking women in 14 European countries. Maturitas. 2005; 52 (2): 25-8.

7. Ermakova E.I., Balan V.E., Tikhomirova E.V., Lazareva I.N., Lapina A.V., Panina E.M. Genitourinary syndrome of menopause: diagnosis and principles of treatment (brief clinical recommendations). Rossiyskiy vestnik akushera-ginekologa [Russian Bulletin of Obstetrician-Gynecologist]. 2017; 17 (6): 89-95. (in Russian)

8. Apolikhina I.A., Yureneva S.V., Malyshkina D.A. Genitourinary syndrome of menopause: contemporary approaches to diagnosis and management. Akusherstvo i ginekologiya [Obstetrics and Gynecology]. Supplement “Diagnostic and Treatment Algorithms”. 2020; 12: 14-8. (in Russian)

9. Angelou K., Grigoriadis T., Diakosavvas M. Zacharakis D., Athana-siou S. The Genitourinary Syndrome of Menopause: An Overview of the Recent Data. Cureus. 2020; 12 (4): 7586. DOI: https://doi.org/10.7759/cureus.7586

10. Smetnik V.P. Yureneva S.V. Ermakova E.I. Glazunova A.V. Genitourinary menopausal syndrome. Diagnostics and treatment (draft clinical protocol). Klimakteriy [Menopause]. 2015; 1. (in Russian)

11. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020; 27 (9): 976-92. DOI: http://dx.doi.org/10.1097/GME.0000000000001609

12. Palacios S., Mejfa A., Neyro J.L. Treatment of the genitourinary syndrome of menopause. Climacteric. 2015; 18 (Suppl 1): 23-9. DOI: https://doi.org/10.3109/13697137.2015.1079100

13. Palacios S., Combalia J., Emsellem C., Gaslain Y., Khorsandi D. Therapies for the management of genitourinary syndrome of menopause. Post Reprod Health. 2020; 26 (1): 32-42. DOI: https://doi.org/10.1177/2053369119866341

14. Baber R.J., Panay N., Fenton A. 2016 IMS Recommendations on women's midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109-50. DOI: https://doi.org/10.3109/13697137.2015.1129166

15. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017; 24 (7): 728-53. DOI: https://doi.org/10.1097/GME.0000000000000921

16. Gambacciani M., Biglia N., Cagnacci A., Caruso S., Cicinelli E, DE Leo V, et al. Menopause and hormone replacement therapy: the 2017 Recommendations of the Italian Menopause Society. Minerva Ginecol. 2018; 70 (1): 27-34. DOI: https://doi.org/10.23736/S0026-4784.17.04151-X

17. Mercier J., Morin M., Tang A., Reichetzer B., Lemieux M.-C., Samir K., Zaki D., Gougeon F., Dumoulin C. Pelvic floor muscle training: mechanisms of action for the improvement of genitourinary syndrome of menopause. Climacteric. 2020; 23 (5): 468-73. DOI: http://dx.doi.org/10.1080/13697137.2020.1724942

18. Mercier J., Melanie M., Zaki D., Reichetzer B., Lemieux M.-C., Khalife S., Dumoulin C. Pelvic floor muscle training as a treatment for genitourinary syndrome of menopause: A single-arm feasibility study. Maturitas. 2019; 125: 57-62. http://dx.doi.org/10.1016/j.maturitas.2019.03.002

19. Filippini M., Luvero D., Salvatore S., Pieralli A., Montera R., Plotti F., Candiani M., Angioli R. Efficacy of fractional CO2 laser treatment in postmenopausal women with genitourinary syndrome: a multicenter study. Menopause. 2020; 27 (1): 43-9. DOI: http://dx.doi.org/10.1097/GME.0000000000001428

20. Paraiso M.F.R., Ferrando C.A., Sokol E.R., Rardin C.R., Matthews C.A., Karram M.M, Iglesia C.B. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause. 2020; 27 (1): 50-6. DOI: http://dx.doi.org/10.1097/GME.0000000000001416

21. Elia D., Gambacciani M.M, Berreni N, Bohbot J.M., Druckmann R., Geoffrion H., Haab F., Heiss N., Rygaloff N., Russo E. Genitourinary syndrome of menopause (GSM) and laser VEL: a review. Horm Mol Biol Clin Investig. 2019; 41 (1). DOI: http://dx.doi.org/10.1515/hmbci-2019-0024

22. Cassani C., Martini E., Zanellini F., Nappi R.E. et.al. Use of a new low-energy dynamic quadripolar radiofrequency (dqrf) device in the treatment of symptoms of vulvo-vaginal atrophy (VVA) in natural menopausal women and breast cancer survivors. 16^th World Congress on Menopause, 2018.

23. Fasola E., Bosoni D. Dynamic Quadripolar Radiofrequency: Pilot Study of a New High-Tech Strategy for Prevention and Treatment of Vulvar Atrophy. Aesthet Surg J. 2019; 39 (5): 544-52. DOI: http://dx.doi.org/10.1093/asj/sjy180

24. Vicariotto F., De Seta F., Faoro V., Raichi M. Dynamic quadripolar radiofrequency treatment of vaginal laxity/menopausal vulvo-vaginal atrophy: 12-month efficacy and safety. Minerva Ginecol. 2017; 69 (4): 342-9. DOI: https://doi.org/10.23736/S0026-4784.17.04072-2. PMID: 28608667

25. Tranchini R., Raichi M. Ultra-Pulsed Radioporation further enhances the efficacy of Dynamic Quadripolar RadioFrequency in women with post-menopausal vulvo-vaginal atrophy. Clin Obstet Gynecol Re-prod Med. 2018; 4 (3): 1-5. DOI: https://doi.org/10.15761/COGRM.1000221.

26. Seregina E.M. EVA ™ - quadripolar dynamic RF-technology for the treatment of urogynecological diseases and aesthetic remodeling of the vulva and vagina. Kosmetika i meditsina [Cosmetics and Medicine]. 2019; (4): 62-8. (in Russian)

27. Prestia V., Bertozzi E., Raichi M. An exploratory, prospective cohort study of non-invasive dynamic quadripolar radiofrequency energy in vulvar lichen management. The new-generation DQRF™ option. Obstet Gynecol Rep. 2021; 5: 1-5. DOI: https://doi.org/10.15761/OGR.10

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)